Business decision

Edmon is the first Communauté Européenne (CE) marked medical device able to continuously measure propofol in the exhaled breath of patients under sedation or anaesthesia with propofol. Current scientific publications indicate that it makes sense from a pharmacologic point of view to measure propofol in the exhaled air.

If the present study can show the Edmon to be able to detect small differences in propofol plasma concentration it will underline the clinical value of measuring propofol in the exhaled breath. This might be an opportunity for a significant improvement in patient monitoring.

• Inclusion criteria

  • Male or female patients undergoing elective surgical procedures
  • Expected duration of the surgical procedure > 1h
  • General anaesthesia (TIVA) with propofol and remifentanil under orotracheal intubation
  • Medical need for an arterial line for an invasive haemodynamic monitoring during anaesthesia
  • Written informed consent
  • Age ≥ 18 years
  • ASA I-III
  • BMI < 35 kg/m²
  • Women of child bearing potential: negative pregnancy test
  • BIS monitoring feasible (e.g. no surgical procedures on the frontal brain)
  • The patient is expected to be extubated in the OR after end of surgery

• Exclusion criteria

  • Patients with contraindications for propofol, remifentanil or for the planned anaesthetic procedure
  • Cardiac surgery
  • Lung surgery
  • Organ transplant procedures
  • Pulmonary diffusion anomalies (e.g. pulmonary fibrosis), known from medical history
  • Patients on renal replacement therapy
  • Participation in another interventional trial
  • Breastfeeding women
  • Unilateral lung ventilation
  • Emergency surgery
  • Patient is not able to give his/her written informed consent
  • Patients with a haemoglobin level below 10 g/dl